Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Ildiko Lingvay's publication output changed over time?
ScholarIQpublication output · 2007–2024
Output grew100% over the shown period — from 1 works in 2007 to 2 in 2024.
1
1
1
1
3
1
2
2
20072016201820192021202220232024
What are the most-cited papers on Ildiko Lingvay?
ScholarIQmost cited works
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso, Stephen C. Bain, Agostino Consoli, Freddy G. Eliaschewitz, Esteban Jódar, Lawrence A. Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark Warren, Vincent Woo, Oluf H. Hansen, Anders G. Holst, Jonas Pettersson, Tina Vilsbøll
New England Journal of Medicine. 20166,751 CitationsOPEN ACCESS
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John Wilding, Rachel L. Batterham, Salvatore Calanna, Melanie J. Davies, Luc F. Van Gaal, Ildiko Lingvay, Barbara McGowan, Julio Rosenstock, Marie Thi Dao Tran, Thomas A. Wadden, Sean Wharton, Koutaro Yokote, Niels Zeuthen, Robert F. Kushner
New England Journal of Medicine. 20214,748 CitationsOPEN ACCESS
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‐Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner, Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Jorge Plutzky, Christoffer W. Tornøe, Donna H. Ryan
New England Journal of Medicine. 20232,815 CitationsOPEN ACCESS
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain
New England Journal of Medicine. 20191,969 CitationsOPEN ACCESS
2. Diagnosis and Classification of Diabetes:<i>Standards of Care in Diabetes—2024</i>
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, Dennis Bruemmer, Billy S. Collins, Laya Ekhlaspour, Jason L. Gaglia, Marisa E. Hilliard, Eric L. Johnson, Kamlesh Khunti, Ildiko Lingvay, Glenn Matfin, Rozalina G. McCoy, Mary Lou Perry, Scott J. Pilla, Sarit Polsky, Priya Prahalad, Richard E. Pratley, Alissa R. Segal, Jane Jeffrie Seley, Elizabeth Selvin, Robert C. Stanton, Robert A. Gabbay
Diabetes Care. 20231,873 CitationsOPEN ACCESS
Related on ScholarIQ
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Paper
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Paper
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Paper
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Paper
2. Diagnosis and Classification of Diabetes:<i>Standards of Care in Diabetes—2024</i>
Paper
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Paper